Patents by Inventor Johan Hoebeke

Johan Hoebeke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multimeric CD40 ligands, method for preparing same and use thereof for preparing drugs
    Patent number: 8357654
    Abstract: A compound of formula (I) is described, wherein Y represents a macrocycle, the ring of which has 9 to 36 atoms, and is functionalized by three amine or COOH functions; Rc represents a group of formula H—Xa—Xb—Xc—Xd—Xe—(Xf)i—, i represents 0 or 1, Xa is in particular lysine, arginine, or ornithine residues, Xb is in particular glycine, asparagine, L-proline or D-proline residues, Xc and Xd are in particular tyrosine, phenylalanine or 3-nitrotyrosine residues, Xe and Xf are in particular amino acid residues: NH2—(CH2)n—COOH, n ranging from 1 to 10, or NH2—(CH2—CH2—O)m—CH2CH2COOH, m ranging from 3 to 6, provided that at least one of the amino acid residues Xa, Xb, Xc and Xd is different from the corresponding amino acid in the sequence of the natural CD40 143Lys-Gly-Tyr-Tyr146 fragment(SEQ ID NO: 1).
    Type: Grant
    Filed: December 15, 2005
    Date of Patent: January 22, 2013
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Gilles Guichard, Sylvie Victorine Lucienne Fournel, Olivier Chaloin, Nathalie Trouche, Sêbastien Wieckowski, Johan Hoebeke
  • Peptides useful as dual caspase-2/-6 inhibitors and their biological applications
    Patent number: 8324173
    Abstract: The present disclosure relates to peptides having a core sequence as described herein as well as application of the disclosed technology as inhibitors of caspase-2 and/or -6 activity.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: December 4, 2012
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: David Chauvier, Richard Casimir, Johan Hoebeke
  • PEPTIDES USEFUL AS DUAL CASPASE-2/-6 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS
    Publication number: 20120021990
    Abstract: The present disclosure relates to peptides having a core sequence as described herein as well as application of the disclosed technology as inhibitors of caspase-2 and/or -6 activity.
    Type: Application
    Filed: July 19, 2011
    Publication date: January 26, 2012
    Inventors: David CHAUVIER, Richard CASIMIR, Johan Hoebeke
  • NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS
    Publication number: 20100183642
    Abstract: The invention concerns a compound of formula (I), wherein Y represents a macrocycle whereof the cycle comprises 9 to 36 atoms, and is functionalized by three amine or COOH functions; Rc represents a group of formula H—Xa—Xb—Xc—Xd—Xe—(Xf)i—, wherein i represents 0 or 1, Xn is in particular selected among lysine, arginine, ornithine residues, Xb is in particular selected among glycine, asparagine, L-proline or D-proline residues, Xc et Xd are in particular selected among tyrosine, phenylalanine or 3-nitrotyrosine residues, Xe et Xf are in particular selected among the following amino acid residues: NH2—(CH2)n—COOH, n ranging from 1 to 10 or NH2—(CH2—CH2—O)m—CH2CH2COOH, m ranging from 3 to 6, provided that one at least of the amino acid residues Xa, Xb, Xc and Xd is different from the corresponding amino acid in the sequence of the natural CD40 143Lys-Gly-Tyr-Tyr146 fragment
    Type: Application
    Filed: December 15, 2005
    Publication date: July 22, 2010
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Gilles Guichard, Sylvie Victorine Lucienne Fournel, Olivier Chaloin, Nathalie Trouche, Sebastien Wieckowski, Johan Hoebeke
  • Screening methods for the identification of inhibitors of human immunodeficiency virus (HIV) viral protein R (Vpr) binding to the adenine nucleotide translocator (ANT)
    Patent number: 7642051
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: January 5, 2010
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite de Technologie de Compiegne
    Inventors: Etienne Daniel Francois Jacotot, Guido Kroemer, Bernard Pierre Roques, Lena Edelman, Johan Hoebeke, Catherine Brenner-Jean, Anne-Sophie Belzacq
  • Peptides Useful As Dual Caspase-2/-6 Inhibitors And Their Biological Applications
    Publication number: 20090042805
    Abstract: The invention relates to peptides having a core sequence selected in the group comprising: SEQ ID No.1: VDEAD, SEQ ID No.2: LDEGD, SEQ ID No.3: VDEGD, SEQ ID No.4: VDESD, SEQ ID No.5: LDEKD, SEQ ID No.6: FDESD, SEQ ID No.7: LDEAD, application as inhibitors of caspase-2 and/or -6 activity.
    Type: Application
    Filed: November 24, 2005
    Publication date: February 12, 2009
    Inventors: David Chauvier, Richard Casimir, Johan Hoebeke
  • Mimetics and inhibitors of the interaction between Vpr (HIV viral protein of regulation) and ANT (Mitochondrial adenine nucleotide translocator)
    Patent number: 7056735
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: June 6, 2006
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite de Technologie de Compiegne
    Inventors: Etienne Daniel Francois Jacotot, Guido Kroemer, Bernard Pierre Roques, Lena Edelman, Johan Hoebeke, Catherine Brenner-Jean, Anne-Sophie Belzacq
  • Mechanism of mitochondrial membrane permeabilization by HIV-1 VPR, mimetics of Vpr and methods of screening active molecules having the ability to alter and/or prevent and/or mimic the interaction of Vpr with ANT
    Publication number: 20060052285
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Application
    Filed: July 8, 2005
    Publication date: March 9, 2006
    Applicants: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite de Technologie de Compiegne
    Inventors: Etienne Jacotot, Guido Kroemer, Bernard Roques, Lena Edelman, Johan Hoebeke, Catherine Brenner-Jean, Anne-Sophie Belzacq
  • Mechanism of mitochondrial membrane permeabilization by HIV-1 Vpr, mimetics of Vpr and methods of screening active molecules having the ability to alter and/or prevent and/or mimic the interaction of Vpr with ANT
    Publication number: 20040072146
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Application
    Filed: March 10, 2003
    Publication date: April 15, 2004
    Inventors: Etienne Daniel Francois Jacotot, Guido Kroemer, Bernard Pierre Roques, Lena Edelmann, Johan Hoebeke, Catherine Brenner-Jan, Anne-Sophie Belzacq
  • Splice variants for human 5-HT4 serotonin receptor and their applications, in particular for screening
    Patent number: 6506580
    Abstract: The invention concerns an isolated polypeptide constitutive of splice variants for human serotonin receptor whereof the amino acid sequence is selected among the sequence SEQ ID No. 2 of the 5-HT4(c) polypeptide variant or the sequence SEQ ID No. 4 of the 5-HT4(d) polypeptide variant, or any polypeptide fragment or biologically active derivative thereof. The invention also concerns the inverse agonist effect of ML 10375 on 5-HT4(c) and 5-HT4(d) receptors.
    Type: Grant
    Filed: September 19, 2000
    Date of Patent: January 14, 2003
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Rodolphe Fischmeister, Michel Langlois, Yamina Dahmoune, Monique Gastineau, Olivier Blondel, Johan Hoebeke
  • Mimetics and inhibitors of the interaction between Vpr (HIV vIral protein of regulation) and ANT (mitochondrial adenine nucleotide translocator)
    Publication number: 20020068273
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Application
    Filed: September 12, 2001
    Publication date: June 6, 2002
    Inventors: Etienne Daniel Francois Jacotot, Guido Kroemer, Bernard Pierre Roques, Lena Edelman, Johan Hoebeke, Catherine Brenner-Jan, Anne-Sophie Belzacq
  • Monoclonal antibodies to legionella, a process for their preparation and their use in the determination of legionella pneumophila
    Patent number: 4780407
    Abstract: A process to produce hybrid cell lines, which produce monoclonal antibodies to Legionella pneumophila. Cell lines are produced by fusion of immunized mouse splenocytes to these bacteria with non secreting myeloma cells.Monoclonal antibodies are useful for diagnosis of diseases due to Legionella pneumophilia, for detection of these bacteria in environment, for the production of vaccines.
    Type: Grant
    Filed: July 1, 1987
    Date of Patent: October 25, 1988
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Arthur D. Strosberg, Jean G. Guillet, Johan Hoebeke, Cuong Tram